9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC

W. Brugger, J.-H. Kim, O. Hansen, R. Sulllivan, S. White, J.-S. Lee, M. Schlegel, J. Noe, I. Nagelmeier, F. Cappuzzo
  • European Journal of Cancer Supplements, September 2009, Elsevier
  • DOI: 10.1016/s1359-6349(09)71889-0

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s1359-6349(09)71889-0

The following have contributed to this page: Dr Federico Cappuzzo